Empowered Patient Podcast

Dr. Nick West is the Chief Medical Officer and Divisional Vice President of Global Medical Affairs at Abbott's Vascular Business. Nick points out the need to make sure the blood vessel is properly closed up at the end of a procedure to ensure no complications. While the Abbott device Perclose™ has been around for quite some time, the ProStyle™ is the new version of it and is a unique suture mediated closure system.

Nick reminds us that, "The old way of doing this is simply to press. Now pressing on the artery, usually, you have to press for at least 10 minutes. If it's done properly, that seals things very nicely, but there are many, many factors that affect the availability of what we call manual compression to seal these punctures. They include where the puncture was, how many times the physician needed to attempt to puncture the vessel before they got into it."

Nick confirms this is the way bleeding has been stopped for hundreds of years and that pressing on the groin is medieval. We talk about how this new approach is a way to effectively close the puncture site in an artery or vein with sutures that allow for primary intentional healing.

@AbbottCardio #AbbottCardio #Perclose #ProStyle #VascularClosure #VascularRepair

Abbott.com

Listen to the podcast here

Dr. Nick West is the Chief Medical Officer and Divisional Vice President of Global Medical Affairs at Abbott's Vascular Business. Nick points out the need to make sure the blood vessel is properly closed up at the end of a procedure to ensure no complications. While the Abbott device Perclose™ has been around for quite some time, the ProStyle™ is the new version of it and is a unique suture mediated closure system.

Nick reminds us that, "The old way of doing this is simply to press. Now pressing on the artery, usually, you have to press for at least 10 minutes. If it's done properly, that seals things very nicely, but there are many, many factors that affect the availability of what we call manual compression to seal these punctures. They include where the puncture was, how many times the physician needed to attempt to puncture the vessel before they got into it."

Nick confirms this is the way bleeding has been stopped for hundreds of years and that pressing on the groin is medieval. We talk about how this new approach is a way to effectively close the puncture site in an artery or vein with sutures that allow for primary intentional healing.

@AbbottCardio #AbbottCardio #Perclose #ProStyle #VascularClosure #VascularRepair

Abbott.com

Download the transcript here

Dr. Marc Semigran is the Chief Medical Officer of Renovacor and shines a light on BAG3-associated cardiomyopathy and the cardiac gene therapy in development to treat this rare genetic disease.

Marc explains, "So, what we are focusing on are patients who have a genetic or familial origin of their dilated cardiomyopathy. Our first target is a gene described as BAG3, which is an important protein within the cardiac muscle cells. And some patients with heart failure have the heart failure because the gene that they have is mutated and is not able to fully express a functional protein."

"We are studying our lead asset, which is REN-001, a modified virus that we believe will specifically target the heart. This will insert into the cardiac muscle cells a good copy of the BAG3 gene, which can then be expressed and allow those cardiac muscle cells to begin to function normally."

#Renovacor #GeneTherapy #DilatedCardiomyopathy #DCM #BAG3 #RareDisease

Renovacor.com

Listen to the podcast here

Dr. Marc Semigran is the Chief Medical Officer of Renovacor and shines a light on BAG3-associated cardiomyopathy and the cardiac gene therapy in development to treat this rare genetic disease.

Marc explains, "So, what we are focusing on are patients who have a genetic or familial origin of their dilated cardiomyopathy. Our first target is a gene described as BAG3, which is an important protein within the cardiac muscle cells. And some patients with heart failure have the heart failure because the gene that they have is mutated and is not able to fully express a functional protein."

"We are studying our lead asset, which is REN-001, a modified virus that we believe will specifically target the heart. This will insert into the cardiac muscle cells a good copy of the BAG3 gene, which can then be expressed and allow those cardiac muscle cells to begin to function normally."

#Renovacor #GeneTherapy #DilatedCardiomyopathy #DCM #BAG3 #RareDisease

Renovacor.com

Download the transcript here

Koenraad Wiedhaup, Founder and CEO of Leyden Labs, and his team have taken a proactive approach to overcome the challenges of protecting people from known viruses and new viruses. They are developing intranasal sprays containing biological molecules that can temporarily protect against a broad range of viruses. This approach is between a vaccine that often gives long-term protection and a therapeutic necessary once someone is infected.

Koenraad says, "This actually gives people the autonomy to protect themselves and to take the nasal spray. And with that, they protect themselves but also others by not transmitting the virus. And indeed, therefore, the additional benefit is that you don't need a healthcare professional to do that. So, which of course, makes such a rollout also easier in the developed world, in places like the US and Europe. But also in more remote areas, where that might be even more important because of the limited availability of healthcare professionals."

@LeydenLabs #LeydenLabs #PandemicPreparedness #coronaviruses #COVID19 #IntranasalMedicine #antiviral #viruses

LeydenLabs.com

Listen to the podcast here

Koenraad Wiedhaup, Founder and CEO of Leyden Labs, and his team have taken a proactive approach to overcome the challenges of protecting people from known viruses and new viruses. They are developing intranasal sprays containing biological molecules that can temporarily protect against a broad range of viruses. This approach is between a vaccine that often gives long-term protection and a therapeutic necessary once someone is infected.

Koenraad says, "This actually gives people the autonomy to protect themselves and to take the nasal spray. And with that, they protect themselves but also others by not transmitting the virus. And indeed, therefore, the additional benefit is that you don't need a healthcare professional to do that. So, which of course, makes such a rollout also easier in the developed world, in places like the US and Europe. But also in more remote areas, where that might be even more important because of the limited availability of healthcare professionals."

@LeydenLabs #LeydenLabs #PandemicPreparedness #coronaviruses #COVID19 #IntranasalMedicine #antiviral #viruses

LeydenLabs.com

Download the transcript here

Dr. Ryan Mathis is the Vice President of Commercial Strategy at PolarityTE, focusing on bringing regenerative medicine into clinical practice, particularly for treating diabetic foot ulcers and other forms of complex wounds.

Ryan says, "So, we're trying to solve this problem by developing SkinTE, which is revolutionizing the science for these hard-to-close wounds. The product itself is an autologous product, meaning we use a patient's own skin to produce the product. Within your skin, there are regenerative cellular populations themselves, most highly focused around your hair follicles, that have the ability to heal wounds. And so, when you normally get a cut, those cells mobilize and move up towards the surface of the skin and heal the wounds."

Listen to the podcast or read the transcript to find out how this innovative treatment creates a paste that gives the wound the ability to heal from the inside out.

@PolarityTE #regenerativemedicine #tissueengineering #skin #woundcare #woundhealing #complexwound #diabetic #diabeticfootulcers

PolarityTE.com

Listen to the podcast here

Dr. Ryan Mathis is the Vice President of Commercial Strategy at PolarityTE, focusing on bringing regenerative medicine into clinical practice, particularly for treating diabetic foot ulcers and other forms of complex wounds.

Ryan says, "So, we're trying to solve this problem by developing SkinTE, which is revolutionizing the science for these hard-to-close wounds. The product itself is an autologous product, meaning we use a patient's own skin to produce the product. Within your skin, there are regenerative cellular populations themselves, most highly focused around your hair follicles, that have the ability to heal wounds. And so, when you normally get a cut, those cells mobilize and move up towards the surface of the skin and heal the wounds."

Listen to the podcast or read the transcript to find out how this innovative treatment creates a paste that gives the wound the ability to heal from the inside out.

@PolarityTE #regenerativemedicine #tissueengineering #skin #woundcare #woundhealing #complexwound #diabetic #diabeticfootulcers

PolarityTE.com

Download the transcript here

Dr. Rob Rohatsch is the Chief Medical Officer at Solv Health and is building an omnichannel strategy for patients, providers, and payers. This approach enables the patients to get urgent or on-demand care from a telehealth visit or the next available in-person visit at a convenient location. The Starbucks model of making it increasingly easy to get the drink of your choice informs the model to meet patients where they are in their lives.

Bob says, "So, we answer three fundamental questions for the patient, which is where should I go? How much is it going to cost? And when can I be seen? So by answering those three fundamental questions really unlocks a lot of power for the patient in the marketplace."

@solvhealth #digitalhealth #urgentcare #telehealth #outpatient #ambulatorycare

SolvHealth.com

Listen to the podcast here

Dr. Rob Rohatsch is the Chief Medical Officer at Solv Health and is building an omnichannel strategy for patients, providers, and payers. This approach enables the patients to get urgent or on-demand care from a telehealth visit or the next available in-person visit at a convenient location. The Starbucks model of making it increasingly easy to get the drink of your choice informs the model to meet patients where they are in their lives.

Bob says, "So, we answer three fundamental questions for the patient, which is where should I go? How much is it going to cost? And when can I be seen? So by answering those three fundamental questions really unlocks a lot of power for the patient in the marketplace."

@solvhealth #digitalhealth #urgentcare #telehealth #outpatient #ambulatorycare

SolvHealth.com

Download the transcript here